Advances in Peritoneal Dialysis: A Review

Seminars in Dialysis

Volumn 25, Issue 5, 2012, Pages 545-549

  Bargman, Joanne M ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; DIALYSIS FLUID;

ARTICLE; ARTIFICIAL MEMBRANE; CHEMISTRY; CHRONIC KIDNEY FAILURE; ECONOMICS; HUMAN; KIDNEY TRANSPLANTATION; METHODOLOGY; MORTALITY; PERITONEAL DIALYSIS; PERITONEAL FIBROSIS; PERITONITIS; RENAL REPLACEMENT THERAPY; SURVIVAL;

BIOLOGICAL MARKERS; DIALYSIS SOLUTIONS; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MEMBRANES, ARTIFICIAL; PERITONEAL DIALYSIS; PERITONEAL FIBROSIS; PERITONITIS; RENAL DIALYSIS; SURVIVAL ANALYSIS;

EID: 84866553898     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2012.01124.x     Document Type: Article

References (29)

1. Ahmad S, Sehmi J, Ahmad-Zakhi K, Clemenger M, Levy J, Brown E: Impact of new dialysis solutions on peritonitis rates. Kidney Int Suppl 103:S63-S66, 2006
2. Montenegro J, Saracho R, Gallardo I, Martinez I, Munoz R, Quintanilla N: Use of pure bicarbonate-buffered peritoneal dialysis fluid reduces the incidence of CAPD peritonitis. Nephrol Dial Transplant 22(6):1703-1708, 2007
3. Furkert J, Zeier M, Schwenger V: Effects of peritoneal dialysis solutions low in GDPs on peritonitis and exit-site infection rates. Perit Dial Int 28(6):637-640, 2008
4. Johnson D, Brown F, Clarke M, Boudville N, Elias T, Foo M, Jones B, Kulkarni H, Langham R, Ranganathan D, Schollum J, Suranyi M, Tan S, Voss D, on behalf of the balANZ Trial Investigators: Effects of biocompatible versus standard fluid on peritoneal dialysis outcomes 23(6):1097-1107, 2012
5. Fan S, Pile T, Punzalan S, Raftery M, Yaqoob M: Randomized controlled study of biocompatible peritoneal dialysis solutions: effect on residual renal function. Kidney Int 73(2):200-206, 2008
6. Haag-Weber M, Kramer R, Haake R, Islam M, Prischl F, Haug U, Nabut J, Deppisch R, on behalf of the DIUREST Study Group: Low-GDP fluid (Gambrosol trio) attenuates decline of residual renal function in PD patients: a prospective randomized study. Nephrol Dial Transplant 25(7):2288-2296, 2010
7. Williams J, Topley N, Craig K, Mackenzie R, Pischetsrieder M, Lage C, Passlick-Deetjen J, Euro Balance Trial Group: The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int 66(1):408-418, 2004
8. Kim S, Oh J, Kim S, Chung W, Ahn C, Kim S, Oh K: Benefits of biocompatible PD fluid for preservation of residual renal function in incident CAPD patients: a 1-year study. Nephrol Dial Transplant 24:2899-2908, 2009
9. Szeto C, Chow K, Lam C, Leung C, Kwan B, Chung K, Law M, Li P: Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation products - a 1-year randomized control trial. Nephrol Dial Transplant 22:552-559, 2007
10. Choi H, Kim D, Lee T, Moon S, Han S, Lee J, Kim B, Park H, Choi K, Ha S, Han D, Lee H: The clinical usefulness of peritoneal dialysis fluids with neutral pH and low glucose degradation product concentration: an open randomized prospective trial. Perit Dial Int 28(2):174-182, 2008
11. Lee H, Park H, Seo B, Do J, Yun S, Song H, Kim Y, Kim Y, Kim D, Kim Y, Ahn C, Kim M, Shin S: Superior patient survival for continuous ambulatory peritoneal dialysis patients treated with a peritoneal dialysis fluid with neutral pH and low glucose degradation product concentration (Balance). Perit Dial Int 25(3):248-255, 2005
12. Lee H, Choi H, Park H, Seo B, Do J, Yun S, Song H, Kim Y, Kim Y, Kim D, Kim Y, Kim M, Shin S: Changing prescribing practice in CAPD patients in Korea: increased utilization of low GDP solutions improves patient outcome. Nephrol Dial Transplant 21(10):2893-2899, 2006
13. Habib S, Betjes M, Fieren M, Boeschoten E, Abrahams A, Boer W, Struijk D, Ruger W, Krikke C, Westerhuis R, de Sevaux R, van der Sande F, Gaasbeek A, Korte M: Management of encapsulating peritoneal sclerosis: a guideline on optimal and uniform treatment. Neth J Med 69(11):500-507, 2011
14. Johnson D, Cho Y, Livingston B, Hawley C, McDonald S, Brown F, Rosman J, Bannister K, Wiggins K: Encapsulating peritoneal sclerosis: incidence, predictors and outcomes. Kidney Int 77(10):904-912, 2010
15. Kawanishi H, Moriishi M: Epidemiology of encapsulating peritoneal sclerosis in Japan. Perit Dial Int Suppl 4:S14-S18, 2005
16. Fieren M, Betjes M, Korte M, Boer W: Posttransplant encapsulating peritoneal sclerosis: a worrying new trend? Perit Dial Int 27(6):619-624, 2007
17. Korte M, Yo M, Betjes M, Fieren M, van Saase J, Boer W, Weimar W, Zietse R: Increasing incidence of severe encapsulating peritoneal sclerosis after kidney transplantation. Nephrol Dial Transplant 22(8):2412-2414, 2007
18. Korte M, Habib S, Lingsma H, Weimar W, Betjes M: Posttransplantation encapsulating peritoneal sclerosis contributes significantly to mortality after kidney transplantation. Am J Transplant 11(3):599-605, 2011
19. Temple S, Zaltzman J, Perl J: Development of encapsulating peritoneal sclerosis in a renal transplant recipient on sirolimus immunotherapy. Perit Dial Int 30(4):475-477, 2010
20. Sampimon D, Korte M, Barreto D, Vlijm A, de Waart R, Struijk D, Krediet R: Early diagnostic markers for encapsulating peritoneal sclerosis: a case-control study. Perit Dial Int 30(2):163-169, 2010
21. Tarzi R, Lim A, Moser S, Ahmad S, George A, Balasubramaniam G, Clutterbuck E, Gedroyc W, Brown E: Assessing the validity of an abdominal CT scoring system in the diagnosis of encapsulating peritoneal sclerosis. Clin J Am Soc Nephrol 3(6):1702-1710, 2008
22. Goodlad C, Tarzi R, Gedroyc W, Lim A, Moser S, Brown E: Screening for encapsulating peritoneal sclerosis in patients on peritoneal dialysis: role of CT scanning. Nephrol Dial Transplant 26(4):1374-1379, 2011
23. Huddam B, Azak A, Kocak G, Basaran M, Voyvoda N, Duranay M: Additive effectiveness of everolimus plus tamoxifen therapy in treatment of encapsulating peritoneal sclerosis. Ren Fail 34(3):387-389, 2012
24. Bargman J: Is there more to living than not dying? A reflection on survival studies in dialysis. Semin Dial 20(1):50-52, 2007
25. Korevaar J, Feith G, Dekker F, van Manen J, Boeschoten E, Bossuyt P, Krediet R, NECOSAD Study Group: Effect of starting with hemodialysis compared with peritoneal dialysis in patients new on dialysis treatment: a randomized controlled trial. Kidney Int 64(6):2222-2228, 2003
26. Chiu Y-W, Jiwakanon S, Lukowsky L, Duong U, Kalantar-Zadeh K, Mehrotra R: An update on the comparisons of mortality outcomes of hemodialysis and peritoneal dialysis patients. Semin Nephrol 31:152-158, 2011
27. Mehrotra R, Chiu Y, Kalantar-Zadeh K, Bargman J, Vonesh E: Hemodialysis and peritoneal dialysis are associated with similar outcomes for end-stage renal disease treatment in the United States. Arch Intern Med 171:110-118, 2011
28. Quinn R, Hux J, Oliver M, Austin P, Tonelli M, Laupacis A: Selection bias explains apparent differential mortality between dialysis modalities. J Am Soc Nephrol 22:1534-1542, 2011
29. Perl J, Wald R, McFarlane P, Bargman J, Vonesh E, Na Y, Jassal S, Moist L: Hemodialysis vascular access modifies the association between dialysis modality and survival. J Am Soc Nephrol 22:1113-1121, 2011